Program
delandistrogene moxeparvovec
Its studies are mostly in Muscular Dystrophy, Duchenne, led by Sarepta Therapeutics.
Furthest: phase 4, since Apr 2, 20261 company-led study, 1 open or runningNext primary completion: Aug 31, 2027 (phase 4)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sarepta Therapeutics | 11 open or running | phase 4since Apr 2, 2026 | Apr 2, 2026 | Aug 31, 2027phase 4 · NCT07542314 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 2, 2026First study: phase 4 study in Muscular Dystrophy, DuchenneFirst studyNCT07542314 · 20 planned · United States
Ahead
- Aug 31, 2027Primary completion: phase 4 study in Muscular Dystrophy, DuchenneNCT07542314
TargetBeta
DMD →read by rule
“Dystrophin exogenous gene”ChEMBL 37, by rule
Other programs on DMD
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| delpacibart zotadirsen | Novartis | phase 3 | 3 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07542314Muscular Dystrophy, Duchenne · United States | 4 | Recruiting | Aug 31, 2027 | 20 |
How it is read
Names in the registry
- “ELEVIDYS”, 1 entry
Conditions, from the studies’ own filings
- Muscular Dystrophy, Duchenne, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.